Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02062203 · ClinicalTrials.gov registry record · Phase 1
Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers
A Phase 1 study, sponsored by Akebia Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT02062203 is a Phase 1 study that has completed, run by Akebia Therapeutics. The registered enrollment target is 50 participants.
The verdict
NCT02062203, a Phase 1 study, has completed, sponsored by Akebia Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the effect of single oral therapeutic and supratherapeutic doses of AKB-6548 on the QT interval.
Interventions
- DRUG Placebo
- DRUG Moxifloxacin
- DRUG AKB-6548 (therapeutic dose)
- DRUG AKB-6548 (supratherapeutic dose)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2014-01 |
| Est. Completion | 2014-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02062203
The ClinicalTrials.gov registry entry for NCT02062203 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Akebia Therapeutics, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02062203 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02062203 about?
NCT02062203 is a clinical study titled "Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers". The main purpose of this study is to evaluate the effect of single oral therapeutic and supratherapeutic doses of AKB-6548 on the QT interval.
What is the current status of trial NCT02062203?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2014-01. Estimated completion is 2014-04.
What interventions are being tested in trial NCT02062203?
The interventions under investigation include: Placebo (DRUG), Moxifloxacin (DRUG), AKB-6548 (therapeutic dose) (DRUG), AKB-6548 (supratherapeutic dose) (DRUG).
Who is sponsoring clinical trial NCT02062203?
This trial is sponsored by Akebia Therapeutics, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.